ライフサイエンスコーパス: cocaine dependence

1 ocaine, a period of high risk for relapse in cocaine dependence.

2 atients in clinical trials of medication for cocaine dependence.

3 ransmission in chronic neural adaptations to cocaine dependence.

4 ing and GDC has promise for the treatment of cocaine dependence.

5 reatment outcomes of community treatments of cocaine dependence.

6 important considerations in the treatment of cocaine dependence.

7 n and withdrawal effects in animal models of cocaine dependence.

8 medications to treat one or more aspects of cocaine dependence.

9 tients with comorbid depressive disorder and cocaine dependence.

10 lication in developing a pharmacotherapy for cocaine dependence.

11 and completion among depressed patients with cocaine dependence.

12 enous opioids has important implications for cocaine dependence.

13 outpatients who meet the DSM-IV criteria for cocaine dependence.

14 bstance use diagnoses, most often opioid and cocaine dependence.

15 ptors have been suggested as medications for cocaine dependence.

16 buting to decreased dopamine transmission in cocaine dependence.

17 coline in patients with bipolar disorder and cocaine dependence.

18 o conclusively rule out neuroinflammation in cocaine dependence.

19 icits in cognitive control are implicated in cocaine dependence.

20 nt might be an effective pharmacotherapy for cocaine dependence.

21 established as an efficacious treatment for cocaine dependence.

22 titute two prominent strategies for treating cocaine dependence.

23 by the opposite directions of risk allele in cocaine dependence.

24 disorder, depressed or mixed mood state, and cocaine dependence.

25 rol purpose in a large case-control study of cocaine dependence.

26 ng might serve as a therapeutic strategy for cocaine dependence.

27 effects may be relevant in the treatment of cocaine dependence.

28 tment with methylphenidate for patients with cocaine dependence.

29 psychological treatments for amphetamine and cocaine dependence.

30 actively using cocaine and had a history of cocaine dependence.

31 the emotional dysregulation associated with cocaine dependence.

32 n response to CRH was independent of sex and cocaine dependence.

33 ficacy of short-term vigabatrin treatment of cocaine dependence.

34 e use of N-acetylcysteine as a treatment for cocaine dependence.

35 ns in dopamine function might be involved in cocaine dependence.

36 next step to increase the ability to manage cocaine dependence.

37 of benefit in improving relapse outcomes in cocaine dependence.

38 compound for agonist substitution therapy in cocaine dependence.

39 ort the role of NSF in the susceptibility to cocaine dependence.

40 iatal dysmorphology in patients with chronic cocaine dependence.

41 t not in short-term outcome of treatment for cocaine dependence.

42 arijuana dependence, 1,262 with histories of cocaine dependence, 647 with amphetamine dependence, and

43 ch compared four psychosocial treatments for cocaine dependence, a three-item craving questionnaire w

44 drug attentional bias effect associated with cocaine dependence (AB-coc) using a word counting Stroop

45 No effective pharmacotherapies exist for cocaine dependence, although contingency management (CM)

46 eatment-seeking cocaine users (CUs) (52 with cocaine dependence and 3 with cocaine abuse) and 56 heal

47 patients with bipolar I disorder and current cocaine dependence and active cocaine use.

48 Crack cocaine dependence and addiction is typically associated

49 volvement of the endogenous opioid system in cocaine dependence and cocaine craving in living human s

50 Alcohol, marijuana, and cocaine dependence and habitual smoking are all familial

51 lial transmission of alcohol, marijuana, and cocaine dependence and habitual smoking in the Collabora

52 Rates of alcohol, marijuana, and cocaine dependence and habitual smoking were increased i

53 indicator, based on co-occurring alcohol and cocaine dependence and poor progress toward achieving in

54 5-HT(1B)Rs may lead to a novel treatment for cocaine dependence and that the therapeutic efficacy of

55 trols) and identified an association between cocaine dependence and the CNV (P = 0.013), that was con

56 al lobes of subjects with a history of crack cocaine dependence and to determine whether these change

57 importance of social-emotional functions in cocaine dependence, and provides a potential underlying

58 odynamic (PD), and predictive biomarkers for cocaine dependence are discussed across a range of metho

59 At present, biomarkers for cocaine dependence are in their infancy.

60 We focus on cocaine dependence as an example.

61 4 control subjects), and the Family Study of Cocaine Dependence (ascertained for cocaine use disorder

62 esent intriguing candidates for the study of cocaine dependence because nicotinic receptors are thoug

63 ram has emerged as a promising treatment for cocaine dependence, but it has not yet been evaluated in

64 condition that predisposes the individual to cocaine dependence by affecting the amygdala, or a prima

65 measurement of craving during treatment for cocaine dependence can monitor patients' clinical status

66 striatal D(2)/D(3 )receptors associated with cocaine dependence cannot be attributed to higher levels

67 lthough craving states are important to both cocaine dependence (CD) and pathological gambling (PG),

68 Cocaine dependence (CD) and related behaviors are highly

69 t a genome-wide association study (GWAS) for cocaine dependence (CD) in three sets of African- and Eu

70 nctional alterations in reward processing in cocaine dependence (CD) pretreatment and posttreatment t

71 vivo in subjects whose primary addiction is cocaine dependence (CD) using positron emission tomograp

72 not been studied previously in persons with cocaine dependence (CD).

73 may be related to the clinical phenotype of cocaine dependence characterized by impulsive behaviours

74 st-would result in efficacious treatment for cocaine dependence compared with placebo.

75 A5-CHRNA3-CHRNB4, in a case-control study of cocaine dependence composed of 504 European-American and

76 psychosocial approaches for the treatment of cocaine dependence: contingency management (CM) and cogn

77 In cocaine dependence, corticostriatal-limbic hyperactivity

78 tive pharmacological agents for treatment of cocaine dependence depends on this knowledge.

79 firam might not be an effective treatment of cocaine dependence for individuals with this variant.

80 Cocaine dependence has been associated with blunted dopa

81 Cocaine dependence impacts drug-related, dopamine-depend

82 Onset preceded the onset of cocaine dependence in 72.0% of the patients (and precede

83 hy volunteers (n=40), persons diagnosed with cocaine dependence in early abstinence (<2 months, EACD)

84 orphisms in the CACNA1D gene associated with cocaine dependence in human subjects.

85 ticoline was well tolerated for treatment of cocaine dependence in patients with bipolar disorder.

86 have both shown promise for the treatment of cocaine dependence in preclinical and early-stage clinic

87 eviously, we identified a risk haplotype for cocaine dependence in the NSF gene, encoding the protein

88 Cocaine dependence involves problematic neuroadaptations

89 Cocaine dependence is a complex psychiatric disorder inv

90 Cocaine dependence is a pervasive disorder with high rat

91 Cocaine dependence is a significant public health proble

92 Cocaine dependence is a substantial public health proble

93 for sex-specific strategies for treatment of cocaine dependence is also furnished by the findings of

94 (PET) imaging studies have demonstrated that cocaine dependence is associated with a decrease in dopa

95 Cocaine dependence is associated with abnormalities in b

96 Cocaine dependence is associated with high rates of rela

97 Cocaine dependence is associated with impairment of dopa

98 Cocaine dependence is associated with severe medical, ps

99 graphy (PET) imaging studies have shown that cocaine dependence is associated with the dysregulation

100 Cocaine dependence is characterized by compulsive drug t

101 While cocaine dependence is prevalent and disabling in women,

102 Relapse vulnerability in cocaine dependence is rooted in genetic and environmenta

103 For example, in cocaine dependence, low dopamine release is associated w

104 tions in the retina, we investigated whether cocaine dependence may be associated with abnormalities

105 its in dopaminergic function associated with cocaine dependence may contribute to striatal hypertroph

106 acy of opioid medications to treat opioid or cocaine dependence may differ by sex.

107 se drug craving and contribute to relapse in cocaine dependence, no previous research has directly ex

108 Eight volunteers with active DSM-IV cocaine dependence not seeking treatment or abstinence w

109 ere we examined the possible contribution to cocaine dependence of a large copy number variant (CNV)

110 nce, especially for patients with concurrent cocaine dependence or abuse.

111 disorder (depressed or mixed mood state) and cocaine dependence received citicoline or placebo add-on

112 probands had an elevated risk of developing cocaine dependence (RR, 1.71).

113 Thus, cocaine dependence seems to engender increased responsiv

114 ffects are a consequence of or antecedent to cocaine dependence, they likely have implications for th

115 ruited 97 treatment-seeking individuals with cocaine dependence to perform the stop signal task durin

116 Cocaine dependence was associated with a marked reductio

117 Cocaine dependence was associated with an extensive syst

118 Greater duration of cocaine dependence was correlated with greater grey matt

119 (5-year) outcomes of community treatment for cocaine dependence were examined in relation to problem

120 in 8 cities) who met DSM-III-R criteria for cocaine dependence when admitted to treatment in 1991-19

121 Cocaine dependence, which affects 2.5 million Americans

122 treatment for most patients with alcohol and cocaine dependence who complete an initial stabilization

123 Patients with cocaine dependence who were receiving methadone maintena

124 llars per year, if developed, biomarkers for cocaine dependence will hold tremendous value to both in

125 in-B) reduces several behavioral measures of cocaine dependence, without altering motor performance o